Beigene
BGNE184.7100.00% ( 0.000 )
Beigene (BGNE)
BeiGene, Ltd., an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and intern...
- Open
- --
- High
- --
- Low
- --
- Prev. Close
- 184.710
- Volume
- 0
- Turnover
- 0
- Avg Price
- --
- Bid/Ask Ratio
- --
- Amplitude
- --
- 52wk High
- 248.160
- Volume Ratio
- 0.00
- Turnover Ratio
- --
News
- Tip Ranks · Jul 27 at 07:35 PM
BeOne Medicines Ltd (6160) Gets a Buy from Nomura
- PUBT · Jul 17 at 04:31 PM
BeOne Medicines CEO John Oyler reports disposal of shares worth $75.72 million
- AASTOCKS News · Jul 13 at 03:20 AM
Macquarie Raises BEONE MEDICINES TP to HKD257, Reiterates Outperform Rating
- Tip Ranks · Jul 12 at 07:25 PM
Analyst Reiterates Buy on BeiGene, Lifts Brukinsa-Driven Outlook and Raises Price Target to $380 Amid Pipeline Progress
- Tip Ranks · Jul 7 at 12:15 AM
Huafu Securities Sticks to Its Buy Rating for BeOne Medicines Ltd (6160)
- StockTitan · Jun 29 at 09:00 PM
BeOne Medicines Announces Positive Phase 3 Results for BRUKINSA in Frontline Mantle Cell Lymphoma | ONC Stock News
